FDA Approves RSV Shot Despite High Infant Risk - AI Podcast

From Dr. Joseph Mercola - Take Control of Your Health Dr. Mercola

Story at-a-glance

Merck's respiratory syncytial virus (RSV) shot clesrovimab (Enflonsia) was approved even though 11.71% of babies in the trial experienced serious adverse events, including seizures, brain injury, and death
Infants who got clesrovimab had a 350% higher risk of upper respiratory infections — exactly the type of illness this shot claims to prevent
The injection is given in a single, fixed dose regardless of infant weight, putting smaller, younger babies at greater risk due to disproportionately high exposure
Babies who received the shot had a threefold increase in severe neurological reactions compared to those given a placebo
Only about 25 babies in the U.S. succumb to RSV each year, making the known risks of clesrovimab far outweigh the threat the virus poses to most children

Lloyd Burrell, Keith Block M.D., Jeffrey Smith, Michael Klaper M.D., Ralph Moss, Brenda Davis R.D., Mark Sloan, Gerald Posner, Ian Harris M.D., Neil Barnard M.D., Will Tuttle Ph.D., John McDougall M.D., Pam Popper Ph.D., Gabriel Cousens M.D., Brian Clement Ph.D., Anna Maria Clement Ph.D., Marianne W

Guided Meditation

Fitness Confidential

Vinnie Tortorich

In Your Right Mind with Monique Rhodes

Monique Rhodes

The Chalene Show | Diet, Fitness & Life Balance

Chalene Johnson

Metabolic Freedom With Ben Azadi

Ben Azadi

The Ultimate Intimacy Podcast

Nick and Amy with The Ultimate Intimacy App

Boundless Body Radio

Casey Ruff

Cat 81 Radio

Por el Placer de Vivir con el Dr. Cesar Lozano

Uforia Podcasts